Study of Talabostat in Advanced Melanoma
NCT00083239 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2007-06-08
Summary
The purpose of this study is to assess the antitumor activity and safety of talabostat in patients with metastatic melanoma.
Conditions
Interventions
- DRUG
-
talabostat (PT-100) tablets
Sponsors & Collaborators
-
Point Therapeutics
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
NCT01323517 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
NCT02439411 ·Status: COMPLETED
-
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
NCT01340729 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients
NCT03374839 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
NCT06008106 ·Status: RECRUITING ·Phase: PHASE3
-
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma
NCT05907512 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
NCT00050102 ·Status: COMPLETED ·Phase: PHASE2
-
Taxoprexin® Treatment for Advanced Eye Melanoma
NCT00244816 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
NCT06961357 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
NCT06965231 ·Status: RECRUITING ·Phase: PHASE2
-
Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients
NCT02285413 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma
NCT00735332 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00004141 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
NCT02535078 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
CP-461 in the Treatment of Patients With Advanced Melanoma
NCT00060710 ·Status: TERMINATED ·Phase: PHASE2
-
Docetaxel With or Without AZD6244 in Melanoma
NCT01256359 ·Status: COMPLETED ·Phase: PHASE2
-
CCI-779 in Treating Patients With Metastatic Melanoma
NCT00022464 ·Status: COMPLETED ·Phase: PHASE2
-
Intratumoral Injections of LL37 for Melanoma
NCT02225366 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tinostamustine and Nivolumab in Advanced Melanoma
NCT03903458 ·Status: UNKNOWN ·Phase: PHASE1
-
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
NCT03454919 ·Status: UNKNOWN ·Phase: PHASE2
-
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
NCT00738361 ·Status: COMPLETED ·Phase: PHASE2
-
RTA 408 Capsules in Patients With Melanoma - REVEAL
NCT02259231 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT05061134 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2